Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Diabetologia

Volumn 59, Issue 7, 2016, Pages 1412-1421

  Tonneijck, Lennart ^a   Smits, Mark M ^a   Muskiet, Marcel H A ^a   Hoekstra, Trynke ^a,b   Kramer, Mark H H ^a   Danser, A H Jan ^c   Diamant, Michaela ^a   Joles, Jaap A ^d   van Raalte, Daniël H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Diabetes; Exenatide; Glomerular filtration rate; Glomerular hyperfiltration; GLP 1 receptor agonist; Glucagon like peptide 1; Renal function; Renal haemodynamics; Type 2 diabetes

Indexed keywords

4 AMINOHIPPURIC ACID; ALBUMIN; EXENDIN 4; GLUCOSE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; POTASSIUM; RENIN; SODIUM; UREA; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; VENOM;

ADULT; AGED; ARTICLE; BODY WATER; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; FRACTIONAL EXCRETION; FREE WATER CLEARANCE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYDROSTATIC PRESSURE; KIDNEY BLOOD FLOW; KIDNEY INJURY; KIDNEY TUBULE FUNCTION; KIDNEY VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSMOTIC DIURESIS; PH; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL CLEARANCE; RENAL SYSTEM PARAMETERS; SODIUM EXCRETION; URINALYSIS; URINE OSMOLALITY; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; KIDNEY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PLACEBO EFFECT;

ADULT; AGED; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMODYNAMICS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MIDDLE AGED; OVERWEIGHT; PEPTIDES; PLACEBO EFFECT; VENOMS;

EID: 84962135632     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-3938-z     Document Type: Article

References (45)

1. Muskiet MH, Tonneijck L, Smits MM et al (2015) Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. Lancet Diabetes Endocrinol 3:367–381
2. Smits MM, Tonneijck L, Muskiet MH et al (2016) Gastrointestinal actions of GLP-1 based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab 18:224–235
3. Muskiet MH, Smits MM, Morsink LM, Diamant M (2014) The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 10:88–103
4. Pendergrass M, Fenton C, Haffner SM, Chen W (2012) Exenatide and sitagliptin are not associated with increased risk of acute renal failure: A retrospective claims analysis. Diabetes Obes Metab 14:596–600
5. Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 373:2247–2257
6. Gutzwiller J-P, Tschopp S, Bock A et al (2004) Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89:3055–3061
7. Thomson SC, Kashkouli A, Singh P (2013) Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am J Physiol Renal Physiol 304:F137–F144
8. Skov J, Dejgaard A, Frøkiær J et al (2013) Glucagon-like peptide-1 (GLP-1): Effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 98:664–671
9. Asmar A, Simonsen L, Asmar M et al (2015) Renal Extraction and Acute Effects of Glucagon-like peptide-1 on Central and Renal Hemodynamics in Healthy Men. Am J Physiol Endocrinol 15(308):E641–E649
10. Muskiet MH, Tonneijck L, Smits MM, Kramer MH, Diamant M, Joles JA et al (2016) Acute renal haemodynamic effects of GLP-1 receptor agonist exenatide in healthy overweight males. Diabetes Obes Metab 18:178–185
11. Smits MM, Tonneijck L, Muskiet MH et al (2015) Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open 19(5):e009579. doi:10.1136/bmjopen-2015-009579
12. Fehse F, Trautmann M, Holst JJ et al (2005) Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90:5991–5997
13. van Bloemendaal L, IJzerman RG, Ten Kulve JS et al (2014) GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 63:4186–4196
14. Heyrovsky A A new method for the determination of inulin in plasma and urine. Clin Chim Acta 1:470–474
15. Waugh WH, Beall PT (1974) Simplified measurement of p-aminohippurate and other arylamines in plasma and urine. Kidney Int 5:429–436
16. Levinsky NG, Levy M (1973) Clearance techniques. In: Geiger SR (ed) Handbook of physiology, section 8: renal physiology. Williams & Wilkins, Baltimore, pp 103–117
17. Gomez DM (1951) Evaluation of renal resistances, with special reference to changes in essential hypertension. J Clin Invest 30:1143–1155
18. Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317:1098
19. Kodera R, Shikata K, Kataoka HU et al (2011) Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54:965–978
20. Von Scholten BJ, Lajer M, Goetze JP et al (2015) Research: Treatment time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med 32:343–352
21. von Scholten BJ, Hansen TW, Goetze JP et al (2015) Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complications 29:670–674
22. Imamura S, Hirai K, Hirai A (2013) The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med 231:57–61
23. Crajoinas RO, Oricchio FT, Pessoa TD et al (2011) Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 301:F355–F363
24. Moreno C, Mistry M, Roman RJ (2002) Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 434:163–167
25. Jensen EP, Poulsen SS, Kissow H et al (2015) Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. Am J Physiol Ren Physiol 308:F867–F877
26. Zhou X, Huang CH, Lao J et al (2015) Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats. Cardiovasc Diabetol 14:29
27. Rieg T, Gerasimova M, Murray F et al (2012) Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Ren Physiol 303:F963–F971
28. Carlstrom M, Wilcox CS, Arendshorst WJ (2015) Renal autoregulation in health and disease. Physiol Rev 95:405–511
29. Vallon V (2003) Tubuloglomerular feedback and the control of glomerular filtration rate. News Physiol Sci 18:169–174
30. Pyke C, Heller RS, Kirk RK et al (2014) GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155:1280–1290
31. Williams SB, Cusco JA, Roddy MA et al (1996) Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27:567–574
32. Dineen SL, McKenney ML, Bell LN et al (2015) Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle. Diabetes 64:3321–3327
33. Smits MM, Muskiet MH, Tonneijck L et al (2016) Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males. Br J Clin Pharmacol 81:613–620
34. Lovshin JA, Barnie A, DeAlmeida A et al (2015) Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes. Diabetes Care 38:132–139
35. McDonough AA, Leong PK, Yang LE (2003) Mechanisms of pressure natriuresis: how blood pressure regulates renal sodium transport. Ann N Y Acad Sci 986:669–677
36. Mendis B, Simpson E, MacDonald I, Mansell P (2012) Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol 74:437–444
37. Ten Kulve JS, van Bloemendaal L, Balesar R et al (2015) Decreased hypothalamic glucagon-like peptide-1 receptor expression in type 2 diabetes patients. J Clin Endocrinol Metab doi:jc20153291
38. Larsen PJ, Tang-Christensen M, Jessop DS (1997) Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138:4445–4455
39. Isbil-Buyukcoskun N, Gulec G (2004) Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept 118:33–38
40. Gutzwiller J-P, Hruz P, Huber AR et al (2006) Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 73:142–150
41. Marina AS, Kutina AV, Natochin YV (2011) Exenatide stimulates solute-free water clearance by the rat kidney in hyperhydration. Dokl Biol Sci 437:85–87
42. Shakhmatova EI, Shutskaia ZV, Vladimirova ME et al (2012) Exenatide stimulated solute-free water excretion by human kidney. Ross Fiziol Zh Im I M Sechenova 98:1021–1029 [Article in Russian: accessed English abstract only]
43. Kutina AV, Marina AS, Shakhmatova EI, Natochin YV (2013) Physiological mechanisms for the increase in renal solute-free water clearance by a glucagon-like peptide-1 mimetic. Clin Exp Pharmacol Physiol 40:510–517
44. Skøtt P, Vaag A, Hother-Nielsen O et al (1991) Effects of hyperglycaemia on kidney function, atrial natriuretic factor and plasma renin in patients with insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 51:715–727
45. Myers GL, Miller WG, Coresh J et al (2006) Recommendations for improving serum creatinine measurement: A report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 52:5–18